SCHEMBL952530

SCHEMBL952530

Cc1nn2ccc(OCCN3CCOCC3)cc2c1-c1nc(-c2ccccc2F)c(-c2ncn(C3CCCCO3)n2)s1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
BRD4 O60885 2/20 0.31
SIGMAR1 Q99720 3/20 0.31
FGFR1 P11362 1/20 0.31
SRC P12931 1/20 0.31
LTA4H P09960 1/20 0.31
ADORA2A P29274 2/20 0.31
ADORA1 P30542 2/20 0.31
NPC1 O15118 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
ADORA2B P29275 1/20 0.31
UBE2N P61088 1/20 0.31
ATR Q13535 1/20 0.31
JAK2 O60674 1/20 0.31
JAK3 P52333 1/20 0.31
PTK2 Q05397 1/20 0.31
HTR2B P41595 1/20 0.31
TNK2 Q07912 1/20 0.30
SYK P43405 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL954973 0.96 HRH3 (0.33) PDE2ATNK2
SCHEMBL953063 0.88 HRH3 (0.33) ADORA2AADORA1ADORA3ADORA2BSYK
SCHEMBL956028 0.88 FGFR1 (0.35) BRD4FGFR1SRCADORA2AADORA1
SCHEMBL951916 0.88 DRD1 (0.32)
SCHEMBL952375 0.86 AVPR1B (0.33) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL953625 0.85 HRH3 (0.32)
SCHEMBL953881 0.85 LTA4H (0.34) SIGMAR1LTA4H
SCHEMBL953372 0.84 CYP4F2 (0.33) ATR
SCHEMBL954160 0.83 PDE2A (0.36) PDE2ASIGMAR1LTA4HADORA2AADORA1
SCHEMBL954397 0.83 SIGMAR1 (0.34) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 PDE2A 1275/4885CD274 1816/4885BRD4 1202/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 PDE2A 2523/4885CD274 1880/4885BRD4 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.